Registry Following Adults With Spread Lobular Breast Cancer
Collects data and blood samples from adults with spread lobular breast cancer.
Plain-language title generated from the registry record
Registry title: Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Key facts
- Where
- Houston, Philadelphia, San Diego, and San Francisco, United StatesSee the 4 sites
Where in United States
- MD Anderson Cancer CenterHouston, United StatesTaking people
- Abramson Cancer CenterPhiladelphia, United StatesTaking people
- University of California San DiegoSan Diego, United StatesTaking people
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT05964504
- Record updated
- 6 November 2026
- Original description
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.Read full original descriptionShow less
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Inclusion: Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed; Age >=18 years; Any receptor subtype; Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion: Other active cancer (prior treated cancer with no current evidence of disease is allowed); Stage I-III breast cancer; Lack of lobular histology on tumor biopsy.